-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2023-509208-14-00
5
2021-09-28
MULTIPLE MYELOMA
-
2024-514473-21-00
5
2021-06-21
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
-
2024-516405-23-00
5
2021-06-08
Acute myeloid leukemia (AML) in second or later complete remission (CR
-
2023-509635-89-00
9
2021-06-01
DIPSS-Intermediate or High Risk Myelofibrosis
-
2024-517761-17-00
4
2021-05-31
Multiple Myeloma
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-506911-16-00
5
2020-12-04
ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
-
2022-502746-27-00
5
2020-08-21
Endometrial Cancer
-
2023-509242-35-00
5
2020-07-23
HR+/HER2- early breast cancer
-
2024-512682-14-00
4
2020-04-06
Non-resectable hepatocellular carcinoma (HCC)
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2024-515375-35-00
4
2019-08-26
Untreated patients with higher risk MDS and oligoblastic AML eligible
-
2024-515769-32-00
5
2019-07-02
HR+/HER2- early breast cancer
-
2024-513464-26-00
5
2018-10-18
Multiple Myeloma
-
2023-506861-76-00
5
2018-08-09
Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplasti
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2024-511791-32-00
4
2017-08-15
Multiple Myeloma
-
2023-505981-26-00
5
2015-11-20
Non−Small Cell Lung Cancer
-
2024-515619-23-00
4
2015-06-29
essential thrombocythemia
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2022-502903-31-00
5
2025-11-05
Patients with ADHD (according to ICD-10 / DSM-5)
-
2024-518841-12-00
9
2025-03-25
HER2 positive resectable esophagogastric adenocarcinoma
-
2024-516641-39-00
7
2024-12-02
Acute Myeloid Leukemia